Glutamatergic Modulation to Facilitate Naltrexone Initiation: A randomized, controlled trial
Medication-Assisted Therapeutic Treatment Research for Opioid Use
Sponsor: NIDA
Enrolling: Male and Female Patients
Study Length: 13 Weeks
IRB Number: 7543
U.S. Govt. ID: NCT03345173
Contact: HOPE Clinic: 646-854-9395 / hopeclinic@nyspi.columbia.edu
Additional Study Information: This free and confidential study is recruiting healthy adults who are currently seeking treatment for opioid use (heroin, painkillers). Participants will be admitted into our inpatient unit for the first 3 to 5 days of the study. In addition to traditional medications used during detoxification, you will also receive innovative, investigative medications that may help with the transition onto Vivitrol (extended-release nalrexone). After discharge from the inpatient unit, participants will engage in twice-weekly outpatient visits for 12 weeks. These visits involve therapy sessions, meeting with a study physician, and completing measures with research assistants. Participants will receive a total of 3 Vivitrol shots throughout the study and will be referred to a community Vivitrol provider once they have completed.
This study is closed
Investigator
Elias Dakwar, MD
Do You Qualify?
Are opioids (heroin or painkillers like Percocet, Oxy, etc.) a problem for you? Yes No
Are you seeking treatment for your opioid use? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
HOPE Clinic
hopeclinic@nyspi.columbia.edu
646-854-9395